Dapagliflozin ameliorates pulmonary arterial hypertension-induced right heart failure via ketone body metabolism and mitochondrial function enhancement.
- DOI
- 10.1016/j.ejphar.2026.179309
- Published
- 2026 Oct 28
- Container
- European journal of pharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejphar.2026.179309,
title = {Dapagliflozin ameliorates pulmonary arterial hypertension-induced right heart failure via ketone body metabolism and mitochondrial function enhancement.},
author = {Xu W and Liu J and Yan L and Er L and Tian S and Du R},
year = {2026},
journal = {European journal of pharmacology},
doi = {10.1016/j.ejphar.2026.179309},
url = {https://doi.org/10.1016/j.ejphar.2026.179309}
}RIS
TY - JOUR TI - Dapagliflozin ameliorates pulmonary arterial hypertension-induced right heart failure via ketone body metabolism and mitochondrial function enhancement. AU - Xu W AU - Liu J AU - Yan L AU - Er L AU - Tian S AU - Du R PY - 2026 JO - European journal of pharmacology DO - 10.1016/j.ejphar.2026.179309 UR - https://doi.org/10.1016/j.ejphar.2026.179309 ER -
APA
W, X., J, L., L, Y., L, E., S, T., & R, D. (2026). Dapagliflozin ameliorates pulmonary arterial hypertension-induced right heart failure via ketone body metabolism and mitochondrial function enhancement.. European journal of pharmacology. https://doi.org/10.1016/j.ejphar.2026.179309
Source records
- pubmed · retrieved 2026-09-25T20:01:59.458Z